$150,000 of IONIS PHARMACEUTICALS INC. lobbying was just disclosed, from Q3 of 2026, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Issues related to the implementation of the Inflation Reduction Act. H.R.1672 - Maintaining Investments in New Innovation Act. H.R.1262/S.932 - Give Kids a Chance Act of 2025. Issues related to drug pricing policy. Issues related to the implementation of the Inflation Reduction Act. H.R.1672 - Maintaining Investments in New Innovation Act. Issues related to the implementation of the Tax Cuts and Jobs Act of 2017. H.R.1414 - Camerons Law."
You can find more data on corporate lobbying on Quiver Quantitative.
IONS Insider Trading Activity
IONS insiders have traded $IONS stock on the open market 29 times in the past 6 months. Of those trades, 2 have been purchases and 27 have been sales.
Here’s a breakdown of recent trading of $IONS stock by insiders over the last 6 months:
- BRETT P MONIA (Chief Executive Officer) has made 0 purchases and 5 sales selling 90,173 shares for an estimated $7,181,536.
- JOSEPH LOSCALZO has made 0 purchases and 2 sales selling 77,289 shares for an estimated $5,801,226.
- HOLLY B. KORDASIEWICZ (EVP, Chief Development Officer) has made 0 purchases and 3 sales selling 61,208 shares for an estimated $4,496,944.
- EUGENE SCHNEIDER (EVP, Chf Clinical Develop Ofcr) sold 26,000 shares for an estimated $2,107,196
- C FRANK BENNETT (EVP, Chief Scientific Officer) has made 0 purchases and 2 sales selling 20,536 shares for an estimated $1,744,623.
- JOSEPH III KLEIN has made 0 purchases and 4 sales selling 21,629 shares for an estimated $1,653,654.
- SPENCER R BERTHELSEN has made 0 purchases and 2 sales selling 16,000 shares for an estimated $1,193,280.
- MICHAEL R HAYDEN has made 2 purchases buying 20,000 shares for an estimated $1,058,700 and 0 sales.
- JOSEPH BAROLDI (EVP, Chief Business Officer) has made 0 purchases and 3 sales selling 12,880 shares for an estimated $987,378.
- ALLENE M. DIAZ sold 10,111 shares for an estimated $863,637
- ERIC SWAYZE (EVP Research) sold 10,602 shares for an estimated $839,491
- KYLE JENNE (EVP, Chf GL Pdt Str Ofcr) sold 4,902 shares for an estimated $368,488
- PATRICK R. O'NEIL (EVP CLO & General Counsel) sold 3,069 shares for an estimated $245,520
- BRIAN BIRCHLER (EVP, Corp and Development Ops) sold 973 shares for an estimated $73,015
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
IONS Hedge Fund Activity
We have seen 242 institutional investors add shares of IONS stock to their portfolio, and 212 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JPMORGAN CHASE & CO added 2,671,717 shares (+inf%) to their portfolio in Q2 2026, for an estimated $211,840,440
- ROYAL BANK OF CANADA added 2,380,664 shares (+62.6%) to their portfolio in Q2 2026, for an estimated $188,762,848
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 1,830,491 shares (-31.6%) from their portfolio in Q2 2026, for an estimated $145,139,631
- SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 1,605,054 shares (+inf%) to their portfolio in Q2 2026, for an estimated $127,264,731
- BARCLAYS PLC added 1,313,262 shares (+453.0%) to their portfolio in Q2 2026, for an estimated $104,128,543
- WELLINGTON MANAGEMENT GROUP LLP added 1,259,599 shares (+19.7%) to their portfolio in Q2 2026, for an estimated $99,873,604
- ALYESKA INVESTMENT GROUP, L.P. added 944,766 shares (+199.7%) to their portfolio in Q2 2026, for an estimated $74,910,496
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
IONS Analyst Ratings
Wall Street analysts have issued reports on $IONS in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Barclays issued a "Overweight" rating on 04/30/2026
To track analyst ratings and price targets for IONS, check out Quiver Quantitative's $IONS forecast page.
IONS Price Targets
Multiple analysts have issued price targets for $IONS recently. We have seen 11 analysts offer price targets for $IONS in the last 6 months, with a median target of $110.0.
Here are some recent targets:
- Joseph Stringer from Needham set a target price of $86.0 on 07/09/2026
- Akash Tewari from Jefferies set a target price of $90.0 on 07/09/2026
- Mitchell S. Kapoor from HC Wainwright & Co. set a target price of $130.0 on 06/25/2026
- Mani Foroohar from Leerink Partners set a target price of $129.0 on 06/25/2026
- Salveen Richter from Goldman Sachs set a target price of $75.0 on 06/25/2026
- Yaron Werber from TD Cowen set a target price of $108.0 on 06/15/2026
- Eric Joseph from Citigroup set a target price of $115.0 on 05/19/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
